Moreover, the magnitude of cytosolic translocation of HMGB1 in the tumor cells before neoadjuvant CRT positively correlated with patient survival, implying cytosolic HMGB1 might be a predictive biomarker of treatment outcome. Here, HMGB1 is linked to neoplasm.